Clinical Trials: Providing New Hope and Opportunity in The Face of Retinal Conditions
Research at Austin Retina
Austin Retina is nationally recognized for its participation in ground-breaking, pivotal clinical trials for over thirty years, which has allowed us to offer our patients the opportunity to receive novel procedures and therapies through enrollment in clinical research studies. We pride ourselves on being at the forefront of clinical research and will always recognize the impact on those who benefit the most: our patients.
For referring doctors or patients who wish to learn more about our research protocols or activities, please continue reading below or contact our office at (512) 451-0103.
Clinical trials are scientific medical research into the appropriateness, effectiveness and safety of new treatments in humans. The goal of clinical trials—whether for vision-related care or any other medical discipline—is to advance medical knowledge and help improve patient care. Specifically, clinical trials determine whether a new medication, device or treatment strategy…
- Improves patient outcomes
- Offers real benefit
- Demonstrates any safety concerns
Designed for safety, accuracy and advancement of quality care.
Clinical trials are designed to produce the highest-quality data possible… while ensuring the safety of the patients in each study. Trials are conducted in adherence to strict standards, and they are governed and reviewed by institutional review boards (IRBs), which exist to protect patients’ health and safety.
Clinical trials are one of the last steps in the careful, detailed process of studying a new treatment. (Investigation begins in the laboratory, and promising methods may proceed to non-human testing and then human trials.) At the same time, patients enrolled in a new treatment’s clinical trial may be the first to benefit from that treatment. Every treatment in use today was investigated and approved for use through the clinical trials process, and all future medical treatments will have gone through this process.
Why consider enrolling in a retina-related clinical trial?
Retinal care, like the field of medicine itself, is always advancing and changing. New methods and medications are constantly being developed to slow disease process, improve vision outcomes, and improve quality of life. At Austin Retina, we participate in clinical trials to offer new options, opportunities and hope for people who seek to protect, preserve or improve their eyesight. For individuals with few options or who aren’t seeing positive results, enrolling in a clinical trial can potentially provide access to additional treatment options.
Clinical trials open for enrollment at Austin Retina.
Our specialists are proud to take part in clinical research trials for many common retinal conditions. Below are trials for which we are currently enrolling new patients. If you’d like more information on any of the trials below, please fill out our contact form and indicate which trial you’re interested in.
Clinical Trials Ongoing
Status: Open for Enrollment
RegenXBio Inc.(Protocol RGX-314-2104) “Atmosphere”
ClinicalTrials.gov Identifier: NCT04704921
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
Regenxbio Inc. (Protocol RGX-314-3101) “Ascent”
ClinicalTrials.gov Identifier: NCT05407636
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.
Opthea Ltd.( (Protocol OPT-1004) “Shore”
ClinicalTrials.gov Identifier: NCT04757610
Phase 3, Multicentre, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Lucentis, Compared with Lucentis Alone.
Opthea “Coast
ClinicalTrials.gov Identifier: NCT04757636
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD).
Ashvattha Therapeutics (Protocol D-4517-002) “Tejas”
ClinicalTrials.gov Identifier: NCT05387837
A phase 2 study of single subcutaneous dose of D-4517.2 in subjects with wAMD or DME.
Kodiak Sciences, Inc. (Protocol KS301P109) “Daybreak”
ClinicalTrials.gov Identifier: NCT06556368
A phase 2 study of single subcutaneous dose of D-4517.2 in subjects with wAMD or DME.
Kalaris Therapeutics, Inc. (Protocol KLRS-100) “KLRS”
ClinicalTrials.gov Identifier:
Phase 3, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 (a fusion protein targeting VEGF-C and VEGF-D) in Combination with Lucentis, Compared with Lucentis Alone
Kyowa Kirin, Inc. (Protocol 4951-002) “KHK-002”
ClinicalTrials.gov Identifier: NCT06116890
A phase 2, multi-center, randomized, double-masked, parallel-group study to assess the efficacy and safety of KHK4951 eye drops, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related macular degeneration (nAMD).
Ocular Therapeutix,Inc. (Protocol OTX-TKI-AMD-301) “Sol”
ClinicalTrials.gov Identifier: NCT06223958
A phase 3, multi-center, double-masked, randomized, parallel-group study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration (nAMD).
Annexon, Inc. (Protocol ANX007-GA-02) “Archer II”
ClinicalTrials.gov Identifier: NCT06510816
A phase 3, multicenter, randomized, parallel-group, double-masked, 2-arm, sham controlled study of the efficacy, safety, and tolerability of ANX007 administered by intravitreal injection in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
DRCR “Protocol AF”
ClinicalTrials.gov Identifier: NCT04661358
A Triple-masked, Randomized trial to Evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening.
Valo Health (Protocol OPL-0401-201) “Spectra”
ClinicalTrials.gov Identifier: NCT05393284
Phase 2 study to evaluate the safety and efficacy of OPL-0401 in patients with non-proliferative diabetic retinopathy OPL-0401 is an oral, small molecule ROCK1/2 inhibitor in development for the treatment of diabetic retinopathy.
Retina Consultants of Texas (Protocol MA00832514) “Magic”
ClinicalTrials.gov Identifier: NCT05383209
Faricimab for retinal non-perfusion associated with non-proliferative diabetic retinopathy: the Magic phase 2, multi-center, open-label, randomized controlled trial.
Kodiak Sciences, Inc. (Protocol KS301P108) “Glow2”
ClinicalTrials.gov Identifier: NCT06270836
A prospective, randomized, double-masked, sham-controlled, multi-center, two-arm, phase 3 study to evaluate the efficacy and safety of intravitreal Tarcocimab Tedromer in treatment naïve participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
JCHR (Protocol AF) “DRCR AF”
ClinicalTrials.gov Identifier: NCT04661358
A triple-masked, randomized trial to evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in eyes with mild to moderately severe non-proliferative diabetic retinopathy (NPDR).
Genentech “GR43828”
ISRCTN Registry Link: doi.org/10.1186/ISRCTN14152148
A phase I, multicenter, open-label study of the safety, tolerability, pharmacokinetics and
immunogenicity of intravitreal injections of RO7446603 alone and co-administered with
Aflibercept or Faricimab in patients with diabetic macular edema.
Quasar
ClinicalTrials.gov Identifier: NCT05850520
A Phase 3 Study of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion.
Unity Biotechnology, Inc. (Protocol UBX1325-04) “Aspire”
ClinicalTrials.gov Identifier: NCT06011798
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema (Aspire).
Kodiak Sciences, Inc. (Protocol KS501P101) “Apex”
ClinicalTrials.gov Identifier:
A phase 2, multi-center, randomized, parallel-group study to assess the efficacy and safety of KHK4951 eye drops, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema (DME).
Eyebiotech, Ltd. (Protocol EYE-TIE-201) “EYE-TIE-201”
ClinicalTrials.gov Identifier: NCT06664502
A phase 1/2a 2-part study consisting of an open-label, multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety, and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).
Eyebiotech, Ltd. (Protocol EYE-RES-102) “Brunello”
ClinicalTrials.gov Identifier: NCT06571045
A randomized, double-masked, multi-center, 3-arm pivotal phase ⅔ study to evaluate the efficacy and safety of intravitreal EYE103 compared with intravitreal ranibizumab (0.5mg) in participants with diabetic macular edema (DME).
Oculis (Protocol DX221) “Diamond 2”
ClinicalTrials.gov Identifier: NCT06172257
A phase 3, double-masked, randomized, multi-center study of the efficacy and safety of OCS-01 eye drops in subjects with diabetic macular edema (DME).
Kyowa Kirin, Inc. (Protocol 4951-003) “KHK-003”
ClinicalTrials.gov Identifier: NCT06116916
A phase 2, multi-center, randomized, parallel-group study to assess the efficacy and safety of KHK4951 eye drops, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema (DME).
Bayer AG (Protocol 22153) “Quasar”
ClinicalTrials.gov Identifier: NCT05850520
Randomized, double-masked, active-controlled, Phase 3 study of the efficacy and safety of Aflibercept 8 mg in macular edema secondary to retinal vein occlusion.
Eyebiotech, Ltd. (Protocol EYE-TIE-201) “EYE-TIE-201”
ClinicalTrials.gov Identifier: NCT06664502
A phase 1/2a 2-part study consisting of an open-label, multiple ascending dose (MAD) safety study in participants with macular edema following branch retinal vein occlusion (BRVO), and a dose-finding, double-masked, comparative safety, and preliminary efficacy study of intravitreal (IVT) EYE201 (Tiespectus) in participants with either diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD).
Kyoto Drug Discovery & Development Co., Ltd. (Protocol KDK-1101-002) “GION”
ClinicalTrials.gov Identifier: NCT06178055
A phase 2, double-masked, randomized, sham-controlled, multiple-dose study of the efficacy and safety of intravitreal KUS121 in the treatment of nonarteritic central retinal artery occlusion (CRAO).
(No studies currently enrolling)
Aura Biosciences, Inc. “Compass”
ClinicalTrials.gov Identifier: NCT06007690
A Phase 3 randomized, masked, controlled trial to evaluate efficacy and safety of Belzupacap Sarotalocan (AU-011) treatment compared to sham control in subjects with primary indeterminate lesion or small choroidal melanoma.
Priovant Therapeutics, Inc. (Protocol PVT-2201-303) “Clarity”
ClinicalTrials.gov Identifier: NCT06431373
A phase 3, randomized, double-masked, placebo-controlled study to investigate the safety and efficacy of oral brepocitinib in adults with active, non-infectious intermediate-, posterior-, and panuveitis.
F. Hoffman-La Roche Limited. (Protocol GP44467) “SatraGo-1”
ClinicalTrials.gov Identifier:
A phase 3, randomized, double-masked, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Satralizumab in participants with moderate-to-severe thyroid eye disease.
Genentech (Protocol GE43220) “Honu”
ClinicalTrials.gov Identifier: NCT05300724
Observational study of the progression of dry AMD patients.
Status: On Hold
Regeneron Pharmaceuticals. (Protocol VGFTe-HD-OD-2444) “Elara”
ClinicalTrials.gov Identifier:
A phase 3b single-arm study of aflibercept 8mg in participants with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).
Status: Closed for Enrollment
Bayer (Protocol 20968) “PULSAR”
ClinicalTrials.gov Identifier: NCT04423718
A phase 2, double-masked, randomized, sham-controlled, multiple-dose study of the efficacy and safety of intravitreal KUS121 in the treatment of nonarteritic central retinal artery occlusion (CRAO).
F. Hoffmann La Roche/Genentech (Protocol GR40844) “AVONELLE-X”
ClinicalTrials.gov Identifier: NCT04777201
Faricimab vs. Aflibercept in Patients With wAMD.
F. Hoffmann La Roche/Genentech (Protocol GR40549) “Portal”
ClinicalTrials.gov Identifier: NCT03683251
A study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration.
Eyebiotech, Ltd. (Protocol EYE103-101) “Amarone”
ClinicalTrials.gov Identifier: NCT05919693
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD).
Clearside. (Protocol CLS1002-202) “Odyssey”
ClinicalTrials.gov Identifier: NCT05850520
A phase 2B study of suprachoroidal administered CLS-AX (Axitinib) in participants with neovascular age-related macular degeneration.
F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”
Faricimab vs. Aflibercept in Patients With wAMD.
F. Hoffmann La Roche/Genentech (Protocol GR40398) “Rhine” Faricimab vs. Aflibercept in Patients With Diabetic Macular Edema
Novartis Pharmaceuticals (Protocol CRTH258B2301) “Kestrel”
Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novo Nordisk (Protocol NN9535-4352) “Focus” – In collaboration with Texas Diabetes & Endocrinology
Semaglutide vs. placebo in Type II diabetics.
F. Hoffmann La Roche/Genentech (Protocol GR40548) “Archway”
Port Delivery System (PDS) vs. Ranibzumab in Patients With wAMD.
Ophthotech (Protocol OPH2005)
Anti-C5 aptamer in patients with Stargardt Disease.
Samsung Bioepis (Protocol SB11-G31-AMD)
Intravitreal SB11 (Proposed Ranibizumab biosimilar) compared to Ranibizumab alone in patients with wAMD.
Ophthotech (Protocol OPH2003)
Anti-C5 aptamer in patients with Geographic Atrophy.
DRCR/JAEB (Protocol W)
AntiVEGF in prevention of vision threatening Diabetic Retinopathy in high risk eyes.
Novartis (Protocol RFB002/Ranibizumab) “RAINBOW”
Ranibizumab vs laser in infants with ROP.
DRCR/JAEB (Protocol TX)
5 Year follow-up exam of subjects who completed DRCR protocol “T”, a comparison of Aflibercept, Bevacizumab and Ranibizumab in patients with DME.
DRCR/JAEB (Protocol AA)
Ultrawide-Field imaging vs traditional 7F fundus photography in patients with diabetic retinopathy in monitoring disease progression.
Unity Biotech “Envision”
UBX1325 vs aflibercept in the treatment of wAMD
Clearside Biomedical “Oasis”
Efficacy and safety of suprachoroidal injection of CLS-AX.
Santen Pharmaceutical Co. “Lumina”
Intravitreal DE-109 vs sham
Eyepoint EYP-2102-001
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
Genentech, Inc. (Protocol ML43000) “Belvedere"
Phase IV study designed to assess the response to treatment with SUSVIMO Q24W in patients with nAMD who have been previously treated with anti-VEGF agents other than ranibizumab.
Age Related Macular Degeneration:
-
Bayer (Protocol 20968) “PULSAR”
ClinicalTrials.gov Identifier: NCT04423718
Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration. -
F. Hoffmann La Roche/Genentech (Protocol GR40844) “AVONELLE-X”
ClinicalTrials.gov Identifier: NCT04777201
Faricimab vs. Aflibercept in Patients With wAMD. -
F. Hoffmann La Roche/Genentech (Protocol GR40549) “Portal”
ClinicalTrials.gov Identifier: NCT03683251
A study to evaluate the long-term safety and tolerability of the port delivery system with Ranibizumab in patients with neovascular age-related macular degeneration. -
UNITY Biotechnology, Inc. (Protocol UBX1325-03) “Envision”
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration. -
EyePoint “Davio2
A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects with Wet AMD. -
Amarone
A 2-part study consisting of an open-label multiple ascending dose (MAD) safety study, and a dose-finding single-masked comparative safety and preliminary efficacy study of intravitreal (IVT) EYE103 in a mixed population of participants with diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). -
Odyssey
A phase 2B study of suprachoroidal administered CLS-AX (Axitinib) in participants with neovascular age-related macular degeneration.
-Henlius Bio. (Protocol HLX04-O-wAMD) “Henlius”**
A Phase I/II, Single-arm, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of HLX04-O Administered by Intravitreal Injection in Subjects With Wet Age Related Macular Degeneration (wAMD).
Non-Proliferative Diabetic Retinopathy:
-
OcuTerra “DR:eam”
A Phase 2 Randomized, Double-Masked, Vehicle- Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR). -
Hoffmann-La Roche (Protocol GR41675) “PAVILION”
ClinicalTrials.gov Identifier: NCT04503551
A Phase III Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy. -
Kodiak Sciences Inc. (Protocol KS301P106) “GLOW”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR). -
Bayer “Neon"
A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately
severe to severe non-proliferative diabetic retinopathy -
Eyepoint “PAVIA"
A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), compared to Sham
Diabetic Macular Edema
-
Hoffmann-La Roche (Protocol GR40550) “Pagoda”
ClinicalTrials.gov Identifier: NCT04108156
A Phase III Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema. -
Adverum Biotechnologies, Inc. (Protocol CRTH258B2305) “INFINITY”
ClinicalTrials.gov Identifier: NCT04418427
A Phase 2 Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema. -
Oculis “Diamond
This trial is a Phase 3 Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema. -
Kodiak “KS501P101
ClinicalTrials.gov Identifier: Pending
This is a Phase 1 Study to investigate the Safety, Tolerability, Bioactivity, and Pharmacokinetics of multiple intravitreal administrations of KSI-501 in Participants with Macular Edema.
Retinal Vein Occlusion
-
Kodiak Sciences Inc. (Protocol KS301P103) “BEACON”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO). -
Hoffmann-La Roche (Protocol GR41984) “BALATON”
A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.
Geographic Atrophy
-
IVERIC bio, Inc. (Protocol ISEE2008)
A Phase 3 Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration. -
Ionis Pharmaceuticals, Inc. “Golden” (Protocol ISIS 696844-CS5)
Phase 2 Placebo-Controlled Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD).
Treatment Studies for All Diseases
- Amgen “ABP938”
An Open Label, Two-Arm Study in Subjects with Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe
Stargardt Disease
- Iveric Bio "OPH2005"
A Phase 2b Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease.
OcuTerra “DR:eam
ClinicalTrials.gov Identifier:
A Phase 2 Randomized, Double-Masked, Vehicle- Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR).
Hoffmann-La Roche (Protocol GR41675) “PAVILION”
ClinicalTrials.gov Identifier: NCT04503551
A Phase III Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy.
Bayer (Protocol 20739) “Neon”
ClinicalTrials.gov Identifier: NCT04722991
A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to
investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately
severe to severe non-proliferative diabetic retinopathy
Hoffmann-La Roche (Protocol GR40550) “Pagoda”
ClinicalTrials.gov Identifier: NCT04108156
A Phase III Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema. \
Adverum Biotechnologies, Inc. (Protocol CRTH258B2305) “INFINITY”
ClinicalTrials.gov Identifier: NCT04418427
A Phase 2 Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema.
Kodiak “KS501P101”
ClinicalTrials.gov Identifier:
A phase 1/1b study to investigate the safety, tolerability, bioactivity, and pharmacokinetics of multiple intravitreal administrations of KSI-501 in participants with diabetic macular edema (DME).
Valo Health (Protocol OPL-0401-201) “Spectra”
ClinicalTrials.gov Identifier: NCT05393284
A phase 2, randomized, double-masked, placebo-controlled, multicenter study to investigate the efficacy and safety of oral OPL-0401, a selective inhibitor of Rho (Ras homolog)-associated kinase, inhibiting ROCK1 and ROCK2 in patients with type 1 or 2 diabetes mellitus who have non-proliferative diabetic retinopathy (NPDR) with or without DME.
Genentech, Inc. (ML43601) “Magic”
ClinicalTrials.gov Identifier: NCT05681884
A triple-masked, randomized trial to evaluate the effect of Fenofibrate, a cholesterol medication, compared with placebo for prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in eyes with mild to moderately severe non-proliferative diabetic retinopathy (NPDR).
(No studies currently enrolled)
IVERIC bio, Inc. (Protocol OPH2005) “STGD1”
ClinicalTrials.gov Identifier: NCT03364153
A Phase 2b Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease.
IVERIC bio, Inc. (Protocol ISEE2008)
ClinicalTrials.gov Identifier: NCT04435366
A Phase 3 Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Ionis Pharmaceuticals, Inc. “Golden” (Protocol ISIS 696844-CS5)
ClinicalTrials.gov Identifier: NCT03815825
Phase 2 Placebo-Controlled Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD).
Genentech “Honu”
ClinicalTrials.gov Identifier: NCT05300724
Observational study of the progression of dry AMD patients.
Clinical Trials Completed:
Opthea (Protocol OPT-302-1002)
Intravitreal OPT-302 in combination with Ranibizumab, compared to Ranibizumab alone in patients with wAMD.
Allergan (Protocol 1771-201-008) “Maple”
Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration.
Allergan (Protocol 150998-006) “SEQUOIA”
Abicipar vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.
Alcon (Protocol RTH258-C001) “HAWK”
RTH258 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
F. Hoffmann La Roche/Genentech (Protocol GX29176) “CHROMA” Phase III
Lampalizumab intravitreal injection vs sham in patients with Geographic Atrophy due to Dry AMD.
Allergan (Protocol 190342-038) “BEACON”
Brimonidine DDS vs Sham in patients with Geographic Atrophy due to Dry AMD.
Regeneron (Protocol R910-3-AMD-1517) “ONYX”
Co-formulation anti-Ang2+Aflibercept for patients with treatment-naïve CNV.
F. Hoffmann La Roche/Genentech (Protocol BP29647) “AVENUE”
RO6867461 vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.
Regeneron (Protocol R2176-3-AMD-1417) “CAPELLA”
REGN2176-3 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
Ophthotech (Protocol OPH1002) “ECLIPSE” Phase III
Intravitreal injections of FOVISTA in combination with Lucentis versus Lucentis as monotherapy in patients with treatment-naïve Wet AMD.
LPath (Protocol LT1009-Oph-003) “NEXUS” Phase 2A
Intravitreal ISONEP (Sonepcizumab LT-1009) as monotherapy or adjunctive therapy to Lucentis, Avastin or Eylea versus Lucentis, Avastin or Eylea as monotherapy in patients with Wet AMD.
NeoVista (Protocol NVI-114) “CABERNET”
Prospective study of the Epi-Rad90 ophthalmic system in patients with subfoveal CNV secondary to AMD.
Regeneron (Protocol VGFT-OD-0910.03)
Safety and tolerability extension study of intravitreal VEGF Trap-Eye in patients with CVN secondary to AMD.
Regeneron (Protocol VGFT-OD-0606) “VIEW”
Safety and efficacy of intravitreal VEGF Trap versus ranibizumab in patients with CNV secondary to AMD.
Genentech (Protocol FVF3426g) “HORIZON”
Intravitreal ranibizumab extension study for patients who have completed a Genentech ranibizumab trial.
Genentech (Protocol FVF4579g) “HARBOR”
Safety and efficacy of 0.5mg and 2.0mg ranibizumab intravitreal injection administered monthly versus as-needed in patients with subfoveal CNV secondary to AMD.
GlaxoSmithKline (Protocol MD7110852)
Dose-evaluation study of pazopanib eye drops versus ranibizumab in patients with CNV secondary to AMD.
Acucela (Protocol 4429-201)
Safety and tolerability of oral ACU-4429 in patients with Dry AMD.
Allergan (Protocol 190342-032D-03)
Safety and efficacy of Brimonidine Tartrate PS DDS in patients with geographic atrophy.
Allergan (Protocol 206207-019)
PS DDS with ranibizumab in patients with CNV secondary to AMD
Allergan (Protocol 211745-001-01) “SIRIUS”
Safety and efficacy of intravitreal AGN211745 in patients with CNV secondary to AMD.
OPKO (Protocol “COBALT”)
Intravitreal bevasiranib versus Lucentis in patients with CNV secondary to AMD.
Genentech (Protocol FVF2587g) “ANCHOR”
Intravitreal ranibizumab versus Visudyne PDT in patients with CNV secondary to AMD.
Genentech (Protocol FVF2598g) “MARINA”
Intravitreal ranibizumab versus sham in occult CNV secondary to AMD.
Genentech (Protocol FVF3192g) “PIER”
Intravitreal ranibizumab in patients with minimally classic CNV secondary to AMD.
Genentech (Protocol FVF3689g) “SAILOR”
Intravitreal ranibizumab in patients with naïve or previously treated CNV secondary to AMD.
Eyetech, Inc./Pfizer (Protocol 1023) “LEVEL”
Intravitreal Macugen in patients with stable, previously treated CNV secondary to AMD.
Alcon Research , Ltd. (Protocol C-02-60)
Juxtascleral anacortave acetate versus sham CNV risk reduction study in patients with Dry AMD.
Alcon Research, Ltd. (Protocol C-01-99)
Juxtascleral anacortave acetate versus sham in patients with predominantly classic CNV secondary to AMD.
CIBA (Protocol BPD OCR-005) “VAM”
Visudyne T-IND study in patients with CNV secondary to AMD.
Miravant/Pharmacia (Protocol SNET2-98EA004)
SnET2 Photodynamic therapy versus sham in patients with CNV secondary to AMD.
Novartis Pharmaceuticals (Protocol CRTH258A2303) “TALON”
Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Age Related Macular Degeneration.
Kodiak Science, Inc. (Protocol KSI301-P107) “Daylight
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD).
Graybug Vision, Inc. (Protocol GBV-102-002) “Altissimo”
GB-102 vs. Aflibercept in Patients With wAMD.
Kodiak Science, Inc. (Protocol KSI301-P107) “Daylight”
This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD).
UNITY Biotechnology, Inc. (Protocol UBX1325-03) “Envision”
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration.
Novartis Pharmaceuticals (Protocol CRTH258A2303) “TALON”
A Phase 2, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Repeat Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration.
Xbrane Biopharma AB (Protocol XBR1001) “Xplore”
Xlucane vs. Ranibzumab in Patients With wAMD.
Novartis Pharmaceuticals (Protocol CRTH258AUS04) “Merlin”
Intravitreal Brolucizumab vs. Aflibercept in wAMD patients with retinal fluid despite frequent anti-VEGF injections.
Chengdu Kanghong Biotech (Protocol KHB-1802) “Panda-2"
Intravitreal Conbercept vs. Aflibercept in patients with treatment-naïve CNV due to wAMD.
University of California, San Francisco (Protocol METforMIN)
Metformin for the Minimization of Geographic Atrophy Progression in Patients with AMD.
F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”
Faricimab vs. Aflibercept in Patients With wAMD.
F. Hoffmann La Roche/Genentech (Protocol GR40398) “Rhine”
Faricimab vs. Aflibercept in Patients With Diabetic Macular Edema
F. Hoffmann La Roche/Genentech (Protocol GR40548) “Archway”
Port Delivery System (PDS) vs. Ranibzumab in Patients With wAMD.
Ophthotech (Protocol OPH2005)
Anti-C5 aptamer in patients with Stargardt Disease.
Samsung Bioepis (Protocol SB11-G31-AMD)
Intravitreal SB11 (Proposed Ranibizumab biosimilar) compared to Ranibizumab alone in patients with wAMD.
Ophthotech (Protocol OPH2003)
Anti-C5 aptamer in patients with Geographic Atrophy.
Novartis (Protocol RFB002/Ranibizumab) “RAINBOW”
Ranibizumab vs laser in infants with ROP.
DRCR/JAEB (Protocol TX)
5 Year follow-up exam of subjects who completed DRCR protocol “T”, a comparison of Aflibercept, Bevacizumab and Ranibizumab in patients with DME.
Opthea (Protocol OPT-302-1002)
Intravitreal OPT-302 in combination with Ranibizumab, compared to Ranibizumab alone in patients with wAMD.
Allergan (Protocol 1771-201-008) “Maple”
Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration.
Allergan (Protocol 150998-006) “SEQUOIA”
Abicipar vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.
Alcon (Protocol RTH258-C001) “HAWK”
RTH258 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
F. Hoffmann La Roche/Genentech (Protocol GX29176) “CHROMA” Phase III
Lampalizumab intravitreal injection vs sham in patients with Geographic Atrophy due to Dry AMD.
Allergan (Protocol 190342-038) “BEACON”
Brimonidine DDS vs Sham in patients with Geographic Atrophy due to Dry AMD.
Regeneron (Protocol R910-3-AMD-1517) “ONYX”
Co-formulation anti-Ang2+Aflibercept for patients with treatment-naïve CNV.
F. Hoffmann La Roche/Genentech (Protocol BP29647) “AVENUE”
RO6867461 vs Lucentis in patients with treatment-naïve CNV due to Wet AMD.
Regeneron (Protocol R2176-3-AMD-1417) “CAPELLA”
REGN2176-3 vs Eylea in patients with treatment-naïve CNV due to Wet AMD.
Ophthotech (Protocol OPH1002) “ECLIPSE” Phase III
Intravitreal injections of FOVISTA in combination with Lucentis versus Lucentis as monotherapy in patients with treatment-naïve Wet AMD.
LPath (Protocol LT1009-Oph-003) “NEXUS” Phase 2A
Intravitreal ISONEP (Sonepcizumab LT-1009) as monotherapy or adjunctive therapy to Lucentis, Avastin or Eylea versus Lucentis, Avastin or Eylea as monotherapy in patients with Wet AMD.
NeoVista (Protocol NVI-114) “CABERNET”
Prospective study of the Epi-Rad90 ophthalmic system in patients with subfoveal CNV secondary to AMD.
Regeneron (Protocol VGFT-OD-0910.03)
Safety and tolerability extension study of intravitreal VEGF Trap-Eye in patients with CVN secondary to AMD.
Regeneron (Protocol VGFT-OD-0606) “VIEW”
Safety and efficacy of intravitreal VEGF Trap versus ranibizumab in patients with CNV secondary to AMD.
Genentech (Protocol FVF3426g) “HORIZON”
Intravitreal ranibizumab extension study for patients who have completed a Genentech ranibizumab trial.
Genentech (Protocol FVF4579g) “HARBOR”
Safety and efficacy of 0.5mg and 2.0mg ranibizumab intravitreal injection administered monthly versus as-needed in patients with subfoveal CNV secondary to AMD.
GlaxoSmithKline (Protocol MD7110852)
Dose-evaluation study of pazopanib eye drops versus ranibizumab in patients with CNV secondary to AMD.
Acucela (Protocol 4429-201)
Safety and tolerability of oral ACU-4429 in patients with Dry AMD.
Allergan (Protocol 190342-032D-03)
Safety and efficacy of Brimonidine Tartrate PS DDS in patients with geographic atrophy.
Allergan (Protocol 206207-019)
PS DDS with ranibizumab in patients with CNV secondary to AMD
Allergan (Protocol 211745-001-01) “SIRIUS”
Safety and efficacy of intravitreal AGN211745 in patients with CNV secondary to AMD.
OPKO (Protocol “COBALT”)
Intravitreal bevasiranib versus Lucentis in patients with CNV secondary to AMD.
Genentech (Protocol FVF2587g) “ANCHOR”
Intravitreal ranibizumab versus Visudyne PDT in patients with CNV secondary to AMD.
Genentech (Protocol FVF2598g) “MARINA”
Intravitreal ranibizumab versus sham in occult CNV secondary to AMD.
Genentech (Protocol FVF3192g) “PIER”
Intravitreal ranibizumab in patients with minimally classic CNV secondary to AMD.
Genentech (Protocol FVF3689g) “SAILOR”
Intravitreal ranibizumab in patients with naïve or previously treated CNV secondary to AMD.
Eyetech, Inc./Pfizer (Protocol 1023) “LEVEL”
Intravitreal Macugen in patients with stable, previously treated CNV secondary to AMD.
Alcon Research , Ltd. (Protocol C-02-60)
Juxtascleral anacortave acetate versus sham CNV risk reduction study in patients with Dry AMD.
Alcon Research, Ltd. (Protocol C-01-99)
Juxtascleral anacortave acetate versus sham in patients with predominantly classic CNV secondary to AMD.
CIBA (Protocol BPD OCR-005) “VAM”
Visudyne T-IND study in patients with CNV secondary to AMD.
Miravant/Pharmacia (Protocol SNET2-98EA004)
SnET2 Photodynamic therapy versus sham in patients with CNV secondary to AMD.
Kodiak Science, Inc. (Protocol KSI-CL-102) “Dazzle”
Phase 2b/3 Active Comparator-controlled Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects With Neovascular (Wet) Age-related Macular Degeneration.
Novartis Pharmaceuticals (Protocol CRTH258A2303) “TALON”
Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Age Related Macular Degeneration.
EyePoint Pharmaceuticals, Inc. (Protocol EYP-1901-001) “DAVIO”
A Phase 1, Open-Label Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD.
F. Hoffmann La Roche/Genentech (Protocol GR40844) “Lucerne”
Faricimab vs. Aflibercept in Patients With wAMD.
Regeneron (Protocol VGFTe-OD-1411) “PANORAMA”
Aflibercept vs sham in patients with NPDR.
Aerpio Therapeutics, Inc. (Protocol AKB-9779-CI-5001) “TIME-2B”
A Novel Tie 2 Activator, AKB-9778, use once or twice daily vs sham in patients with NPDR.
Clearside Biomedical (Protocol CLS1004-201) “TYBEE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in DME.
Roche (Protocol BP30099) “BOULEVARD”
Anti-VEGF + anti-Ang2 for patients with DME.
Regeneron (Protocol R910-3-DME-1518) “RUBY”
Co-formulation anti-Ang2+Aflibercept for patients with DME.
Allegro (Protocol DME-202B) “Del Mar” Stage 1 and 2
Luminate vs Avastin in patients with DME.
Allegro (Protocol PVD-202) “Pacific”
Luminate vs BSS for PVD inducement in patients with NPDR.
Allergan (Protocol 150998-004) “PALM”
Evaluation of Abicipar Pegol (AGN-150998) versus ranibizumab in patients with vision loss due to diabetic macular edema.
Aerpio Therapeutics, Inc. (Protocol AKB-9778-CI-2003)
Safety and efficacy of daily, subcutaneous AKB-9778 injections as monotherapy or adjunctive therapy to ranibizumab vs. ranibizumab as monotherapy in patients with diabetic macular edema.
DRCR/JAEB (Protocol U)
Evaluation of combination corticosteroid plus anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes.
Regeneron (Protocol VGFT-OD-1009.01) “VISTA”
Safety and efficacy of intravitreal VEGF Trap-Eye in patients with diabetic macular edema.
iCo Therapeutics (Protocol 2010-007-03-DME) “iDEAL”
Intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in patients with foveal diabetic macular edema.
DRCR/JAEB (Protocol T)
Comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab in patients with diabetic macular edema.
DRCR/JAEB (Protocol GEN)
Genes in Diabetic Retinopathy Project.
DRCR/JAEB (Protocol V)
Prompt laser + deferred aflibercept vs. Observation + deferred aflibercept vs. Prompt aflibercept, (1:1:1), for the treatment of diabetic macular edema in treatment-naïve patients with very good vision (20/25 or better).
DRCR (Protocol S)
Prompt PRP versus intravitreal ranibizumab with deferred PRP in patients with proliferative diabetic retinopathy.
Allergan (Protocol 206207-024)
Comparing the safety and efficacy of dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.
Genentech (Protocol FVF4170g) “RISE”
Safety and efficacy of intravitreal ranibizumab versus sham injection in patients with clinically significant macular edema secondary to diabetes mellitus.
Allergan (Protocol 206207-011)
Dexamethasone PS DDS versus sham in patients with diabetic macular edema.
DRCR/JAEB (Protocol 1A)
Modified laser treatment in patients with diabetic macular edema.
DRCR/JAEB (Protocol B)
Observation of diabetic macular edema following scatter laser therapy.
DRCR/JAEB (Protocol F)
Triamcinolone with focal laser in patients with diabetic macular edema.
Allergan (Protocol 206207-018)
PS DDS in patients with diabetic macular edema status post vitrectomy.
Alimera Sciences , Inc. (Protocol C-01-05-001) “FAME”
Intravitreal Fluocinolone Acetonide versus sham in patients with diabetic macular edema.
Oxular “Cape”
A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered with the Oxulumis® Ophthalmic Administration Device in Subjects with Diabetic Macular Edema.
Oxurion “Kalahari” (Protocol THR-149-002)
This is a Phase 2 Study of the Efficacy and Safety of THR-149 versus aflibercept in Subjects With Diabetic Macular Edema.
Kodiak Sciences Inc. (Protocol KS301P106) “GLOW”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR).
Kodiak Sciences Inc (Protocol KS301P104) “GLEAM”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
Hoffmann-La Roche (Protocol KS301P105) “GLIMMER”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
Hoffmann-La Roche (Protocol GR41987) “Rhone-X”
Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema.
Novartis Pharmaceuticals (Protocol CRTH258D2301) “CONDOR”
Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy.
Kodiak Sciences Inc. (Protocol KS301P106) “GLOW”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR).
Kodiak Sciences Inc (Protocol KS301P104) “GLEAM”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
Hoffmann-La Roche (Protocol KS301P105) “GLIMMER”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
Hoffmann-La Roche (Protocol GR41987) “Rhone-X”
Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema.
Novartis Pharmaceuticals (Protocol CRTH258D2301) “CONDOR”
Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
DRCR/JAEB (Protocol W)
AntiVEGF in prevention of vision threatening Diabetic Retinopathy in high risk eyes.
DRCR/JAEB (Protocol AA)
Ultrawide-Field imaging vs traditional 7F fundus photography in patients with diabetic retinopathy in monitoring disease progression.
Novartis Pharmaceuticals (Protocol CRTH258B2301) “Kestrel”
Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Novo Nordisk (Protocol NN9535-4352) “Focus” – In collaboration with Texas Diabetes & Endocrinology
Semaglutide vs. placebo in Type II diabetics.
DRCR/JAEB (Protocol AE)
Photobiomodulation compared with sham for the Treatment of CI-DME
Opthea (Protocol OPT-302-1003)
Intravitreal OPT-302 in combination with Aflibercept, compared to Aflibercept alone in patients with Diabetic Macular Edema.
DRCR/JAEB (Protocol AC)
Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME
Regeneron (Protocol VGFTe-OD-1411) “PANORAMA”
Aflibercept vs sham in patients with NPDR.
Aerpio Therapeutics, Inc. (Protocol AKB-9779-CI-5001) “TIME-2B”
A Novel Tie 2 Activator, AKB-9778, use once or twice daily vs sham in patients with NPDR.
Clearside Biomedical (Protocol CLS1004-201) “TYBEE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in DME.
Roche (Protocol BP30099) “BOULEVARD”
Anti-VEGF + anti-Ang2 for patients with DME.
Oxular “Cape”
A Multi-Center, Randomized, Two-Arm, Parallel-Group, Single-masked, 24-week, Clinical Trial to Evaluate Safety and Tolerability of Two Dose Levels of Suprachoroidal Triamcinolone Acetonide Administered with the Oxulumis® Ophthalmic Administration Device in Subjects with Diabetic Macular Edema.
Oculis “Diamond” (Protocol DX219)
This trial is a Phase 3 Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema.
Regeneron (Protocol R910-3-DME-1518) “RUBY”
Co-formulation anti-Ang2+Aflibercept for patients with DME.
Allegro (Protocol DME-202B) “Del Mar” Stage 1 and 2
Luminate vs Avastin in patients with DME.
Allegro (Protocol PVD-202) “Pacific”
Luminate vs BSS for PVD inducement in patients with NPDR.
Allergan (Protocol 150998-004) “PALM”
Evaluation of Abicipar Pegol (AGN-150998) versus ranibizumab in patients with vision loss due to diabetic macular edema.
Aerpio Therapeutics, Inc. (Protocol AKB-9778-CI-2003)
Safety and efficacy of daily, subcutaneous AKB-9778 injections as monotherapy or adjunctive therapy to ranibizumab vs. ranibizumab as monotherapy in patients with diabetic macular edema.
DRCR/JAEB (Protocol U)
Evaluation of combination corticosteroid plus anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes.
Regeneron (Protocol VGFT-OD-1009.01) “VISTA”
Safety and efficacy of intravitreal VEGF Trap-Eye in patients with diabetic macular edema.
iCo Therapeutics (Protocol 2010-007-03-DME) “iDEAL”
Intravitreal injections of iCo-007 as monotherapy or in combination with ranibizumab or laser photocoagulation in patients with foveal diabetic macular edema.
DRCR/JAEB (Protocol T)
Comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab in patients with diabetic macular edema.
DRCR/JAEB (Protocol GEN)
Genes in Diabetic Retinopathy Project.
DRCR/JAEB (Protocol V)
Prompt laser + deferred aflibercept vs. Observation + deferred aflibercept vs. Prompt aflibercept, (1:1:1), for the treatment of diabetic macular edema in treatment-naïve patients with very good vision (20/25 or better).
DRCR (Protocol S)
Prompt PRP versus intravitreal ranibizumab with deferred PRP in patients with proliferative diabetic retinopathy.
Allergan (Protocol 206207-024)
Comparing the safety and efficacy of dexamethasone posterior segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema.
Hoffmann-La Roche (Protocol GR40398) “RHINE”
PA Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE).
Genentech (Protocol FVF4170g) “RISE”
Safety and efficacy of intravitreal ranibizumab versus sham injection in patients with clinically significant macular edema secondary to diabetes mellitus.
Allergan (Protocol 206207-011)
Dexamethasone PS DDS versus sham in patients with diabetic macular edema.
DRCR/JAEB (Protocol 1A)
Modified laser treatment in patients with diabetic macular edema.
DRCR/JAEB (Protocol B)
Observation of diabetic macular edema following scatter laser therapy.
DRCR/JAEB (Protocol F)
Triamcinolone with focal laser in patients with diabetic macular edema.
Allergan (Protocol 206207-018)
PS DDS in patients with diabetic macular edema status post vitrectomy.
Alimera Sciences , Inc. (Protocol C-01-05-001) “FAME”
Intravitreal Fluocinolone Acetonide versus sham in patients with diabetic macular edema.
Novartis Pharmaceuticals (Protocol CRTH258B2305) “KINGFISHER”
Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema.
Adverum Biotechnologies, Inc. (Protocol CRTH258B2305) “INFINITY”
A Phase 2 Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema.
Regeneron Pharmaceuticals (Protocol VGFTe-HD-DME-1934) “PHOTON”
Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema.
Clearside Biomedical (Protocol CLS1003-302) “Topaz”
Supra-choroidal Triamcinolone with Intravitreal Anti-VEGF vs sham Suprachoroidal procedure with Intravitreal Anti-VEGF in RVO with ME.
Clearside Biomedical (Protocol CLS1003-301) “SAPPHIRE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in RVO with ME.
Allergan (Protocol 208397-001)
Safety and efficacy of a single dose of AGN-208397 in patients with macular edema due to retinal vein occlusion.
Genentech (Protocol FVF4165g) “BRAVO”
Ranibizumab versus sham in patients with branch retinal vein occlusion.
Genentech (Protocol FVF4166g) “CRUISE”
Intravitreal ranibizumab versus sham in patients with central retinal vein occlusion.
Hoffmann-La Roche (Protocol GR41986) “COMINO”
A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
Genentech (Protocol FVF4967g ) “SHORE”
Dosing regimens of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Allergan (Protocol 206207-009)
Intravitreal dexamethasone PS DDS versus sham in patients with central or branch retinal vein occlusion.
Kodiak Sciences Inc. (Protocol KS301P103)
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).
Aerie Pharmaceuticals, Inc. (Protocol AR-1105-CS201) “Orion”
This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO).
Clearside Biomedical (Protocol CLS1003-302) “Topaz”
Supra-choroidal Triamcinolone with Intravitreal Anti-VEGF vs sham Suprachoroidal procedure with Intravitreal Anti-VEGF in RVO with ME.
Clearside Biomedical (Protocol CLS1003-301) “SAPPHIRE”
Supra-choroidal Triamcinolone with Intravitreal Aflibercept vs sham Suprachoroidal procedure with Intravitreal Aflibercept in RVO with ME.
Allergan (Protocol 208397-001)
Safety and efficacy of a single dose of AGN-208397 in patients with macular edema due to retinal vein occlusion.
Genentech (Protocol FVF4165g) “BRAVO”
Ranibizumab versus sham in patients with branch retinal vein occlusion.
Genentech (Protocol FVF4166g) “CRUISE”
Intravitreal ranibizumab versus sham in patients with central retinal vein occlusion.
Hoffmann-La Roche (Protocol GR41986) “COMINO”
A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion.
Genentech (Protocol FVF4967g ) “SHORE”
Dosing regimens of intravitreal ranibizumab in patients with macular edema secondary to retinal vein occlusion.
Allergan (Protocol 206207-009)
Intravitreal dexamethasone PS DDS versus sham in patients with central or branch retinal vein occlusion.
Kodiak Sciences Inc. (Protocol KS301P103) “BEACON”
Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).
Hoffmann-La Roche (Protocol GR41984) “BALATON”
A Phase III Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion.
Mallinckrodt (Protocol MNK61074105)
Acthar in patients with severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Eyegate (Protocol EGP-437-006)
Iontophorectic dexamethasone for non-infectious anterior Uveitis.
Clearside Biomedical (Protocol CLS1001-301) “Peachtree”
Supra-choroidal Triamcinolone for non-infectious Uveitis.
Santen (Protocol 32-007) “SAKURA”
Safety and efficacy of DE-109 for the treatment of active, non-infectious posterior segment uveitis.
EyeGate (Protocol EGP-437-004)
Safety and efficacy of iontophoretic dexamethasone phosphate compared to prednisolone acetate 1% in patients with non-infectious anterior segment uveitis.
Mallinckrodt (Protocol MNK61074105)
Acthar in patients with severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Eyegate (Protocol EGP-437-006)
Iontophorectic dexamethasone for non-infectious anterior Uveitis.
Clearside Biomedical (Protocol CLS1001-301) “Peachtree”
Supra-choroidal Triamcinolone for non-infectious Uveitis.
Santen (Protocol 32-007) “SAKURA”
Safety and efficacy of DE-109 for the treatment of active, non-infectious posterior segment uveitis.
EyeGate (Protocol EGP-437-004)
Safety and efficacy of iontophoretic dexamethasone phosphate compared to prednisolone acetate 1% in patients with non-infectious anterior segment uveitis.
Alcon Research, LTD. (Protocol C-04-18)
Evaluation of BSS irrigating solution during vitrectomy.
Inspire (Protocol 06-102)
Intravitreal Denufosol in patients with rhegmatogenous retinal detachment.
Alcon Research, LTD. (Protocol C-04-18)
Evaluation of BSS irrigating solution during vitrectomy.
Inspire (Protocol 06-102)
Intravitreal Denufosol in patients with rhegmatogenous retinal detachment.
Allegro Ophthalmics, LLC (Protocol VMA-202)
Safety and efficacy of intravitreal ALG-1001 vs. BSS injection in patients with symptomatic vitreomacular adhesion.
ThromboGenics (Protocol TG-MV-006) “MIVI-TRUST”
Microplasmin intravitreal injection versus sham injection in patients with vitreomacular traction.
Allegro Ophthalmics, LLC (Protocol VMA-202)
Safety and efficacy of intravitreal ALG-1001 vs. BSS injection in patients with symptomatic vitreomacular adhesion.
ThromboGenics (Protocol TG-MV-006) “MIVI-TRUST”
Microplasmin intravitreal injection versus sham injection in patients with vitreomacular traction.
DigiSight (Protocol DS2001510k) “PAXOS Checkup”
Mobile device self visual acuity testing vs ETDRS.
Rohrer (Protocol 513403-T)
Pharmacokinetics and safety of lomefloxacin eye drops.
Parke-Davis (Protocol 919-220-0)
A multiple dose safety study on enoxacin eye drops.
Otsuka (Protocol 67-90-201)
Pharmacokinetics and safety of OPC-14117 eye drops.
Pharmos (Protocol P-5604:107)
Safety and efficacy of loteprednol etabonate in patients with GPC secondary to contact lens wear.
Genentech, Inc. (Protocol GR40973) “GALLEGO”
A Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Genentech, Inc. (Protocol GR40973) “GALLEGOLE”
Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Diopsys, Inc. “Indigo”
Evaluation of retinal function in eyes with diabetic retinopathy treated with anti-VEGF using Flicker ERG
Amgen “ABP938”
An Open Label, Two-Arm Study in Subjects with Chorioretinal Vascular Disease to Evaluate ABP 938 and Aflibercept (Eylea®) in a Prefilled Syringe
Verily Life Sciences, LLC “ARDA-003”
Evaluation of investigational retinal imaging camera study
DigiSight (Protocol DS2001510k) “PAXOS Checkup”
Mobile device self visual acuity testing vs ETDRS.
Rohrer (Protocol 513403-T)
Pharmacokinetics and safety of lomefloxacin eye drops.
Parke-Davis (Protocol 919-220-0)
A multiple dose safety study on enoxacin eye drops.
Otsuka (Protocol 67-90-201)
Pharmacokinetics and safety of OPC-14117 eye drops.
Pharmos (Protocol P-5604:107)
Safety and efficacy of loteprednol etabonate in patients with GPC secondary to contact lens wear.
Genentech, Inc. (Protocol GR40973) “GALLEGOLE”
Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Genentech, Inc. (Protocol GR40973) “GALLEGO”
A Phase II Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
